Cat.#: ASSD-128
Description | Fluorescent M3 muscarinic receptor antagonist (apparent KD values are 7.97, 6.29 and 6.24 for M3, M5 and M1 receptors respectively). Antagonizes the activity of carbachol, a muscarinic receptor agonist. Displays no intrinsic activity. |
Synonyms | M3-633-AN |
Size | 50 μg |
Applications | For imaging at the M3 receptor use solutions up to 100 nM. |
Molecule Weight | 1014 |
Purity | >97% |
Solubility | Soluble in DMSO |
Excitation | 633 nm |
Emission | 650 nm |
Storage | Store at -20° C |
Shipping | Shipped at 4°C |
Important | We strongly recommend storing this product away from light and briefly sonicating the sample when using to ensure it is fully dissolved and the solution is homogeneous. However, we do not recommend using the product after subjecting it to repetitive freeze-thaw cycles. |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Size | Price |
---|---|---|---|
ASSD-225 | Antifade Fluorescence Mounting Medium with Propidium Iodide (aqueous) (AC225) | 10 mL | inquiry |
ASSD-125 | Fluorescent D1 antagonist [SKF83566-green] (AC125) | 50 μg | inquiry |
ASSD-183 | 5-(4,6-Dichloro-s-triazin-2-ylamino)fluorescein hydrochloride (AC183) | 100 mg | inquiry |
ASSD-196 | 5-Carboxyfluorescein (AC196) | 100 mg, 250 mg | inquiry |
ASSD-213 | Fluorescein 6-Maleimide (AC213) | 25 mg, 250 mg | inquiry |
ASSD-173 | FITC-Dextran 70 (AC173) | 100 mg, 500 mg | inquiry |
ASSD-149 | D-Luciferin sodium salt (AC149) | 10 mg, 50 mg, 100 mg | inquiry |
ASSD-200 | Ethylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[3-difluoromethyl-4-phosphoanilinamidosuccinic Acid] Diamide (AC200) | 500 μg | inquiry |
ASSD-106 | Hoechst 33342 Staining Solution (10mg/ml) (AC106) | 5 mL, 10 mL | inquiry |
ASSD-141 | MTT (AC141) | 500 mg, 1 g | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.